错配修复缺陷-话题@MedSci

#错配修复缺陷#

9篇内容 | 778人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2192497, encodeId=32dd219249e2b, content=<a href='/topic/show?id=1a5a58e00ad' target=_blank style='color:#2F92EE;'>#新辅助治疗#</a> <a href='/topic/show?id=34b54848271' target=_blank style='color:#2F92EE;'>#帕博利珠单抗#</a> <a href='/topic/show?id=20c296e40e2' target=_blank style='color:#2F92EE;'>#错配修复缺陷#</a> <a href='/topic/show?id=38be11214486' target=_blank style='color:#2F92EE;'>#微卫星不稳定高#</a>, objectTitle=JCO：新辅助帕博利珠单抗治疗局部错配修复缺陷(dMMR)/微卫星不稳定高(MSI-H)实体瘤, objectType=article, longId=816666, objectId=9e7f816666d0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/333.jpg, objectUrl=/article/show_article.do?id=9e7f816666d0, replyNumber=0, likeNumber=16, createdTime=2024-03-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=9e7f816666d0, moduleTitle=JCO：新辅助帕博利珠单抗治疗局部错配修复缺陷(dMMR)/微卫星不稳定高(MSI-H)实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e7f816666d0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1645539, encodeId=e91616455394b, content=<a href='/topic/show?id=20c296e40e2' target=_blank style='color:#2F92EE;'>#错配修复缺陷#</a>, objectTitle=Lancet Oncol：派姆单抗 vs 化疗治疗微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的长期预后, objectType=article, longId=724610, objectId=793de2461036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=793de2461036, replyNumber=0, likeNumber=50, createdTime=2022-06-11, rootId=0, userName=李研东, userId=a68823222118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=793de2461036, moduleTitle=Lancet Oncol：派姆单抗 vs 化疗治疗微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=793de2461036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645538, encodeId=6fef164553824, content=<a href='/topic/show?id=20c296e40e2' target=_blank style='color:#2F92EE;'>#错配修复缺陷#</a>, objectTitle=Nat Cancer：化疗和错配修复缺陷协同促进TP53突变的发生和急性淋巴细胞白血病的复发, objectType=article, longId=214726, objectId=0cd1214e26c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cd1214e26c8, replyNumber=0, likeNumber=49, createdTime=2022-05-23, rootId=0, userName=李研东, userId=a68823222118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cd1214e26c8, moduleTitle=Nat Cancer：化疗和错配修复缺陷协同促进TP53突变的发生和急性淋巴细胞白血病的复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cd1214e26c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645537, encodeId=ab7d164553eea, content=<a href='/topic/show?id=20c296e40e2' target=_blank style='color:#2F92EE;'>#错配修复缺陷#</a>, objectTitle=复发或晚期错配修复缺陷的子宫内膜癌：Dostarlimab的临床活性和安全性, objectType=article, longId=206100, objectId=b08320610035, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b08320610035, replyNumber=0, likeNumber=37, createdTime=2021-08-17, rootId=0, userName=李研东, userId=a68823222118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b08320610035, moduleTitle=复发或晚期错配修复缺陷的子宫内膜癌：Dostarlimab的临床活性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b08320610035)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645534, encodeId=b7da1645534ff, content=<a href='/topic/show?id=20c296e40e2' target=_blank style='color:#2F92EE;'>#错配修复缺陷#</a>, objectTitle=Oncologist：Nivolumab加低剂量Ipilimumab为既往治疗的微卫星不稳定及高/错配修复缺陷型转移性结直肠癌患者提供新的治疗选择, objectType=article, longId=201431, objectId=64b22014318f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64b22014318f, replyNumber=0, likeNumber=38, createdTime=2020-12-19, rootId=0, userName=李研东, userId=a68823222118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64b22014318f, moduleTitle=Oncologist：Nivolumab加低剂量Ipilimumab为既往治疗的微卫星不稳定及高/错配修复缺陷型转移性结直肠癌患者提供新的治疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64b22014318f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645536, encodeId=37ad164553609, content=<a href='/topic/show?id=20c296e40e2' target=_blank style='color:#2F92EE;'>#错配修复缺陷#</a>, objectTitle=ASCO GI 2020：dostarlimab在错配修复缺陷（dMMR）实体瘤取得积极疗效数据, objectType=article, longId=205841, objectId=b4b220584147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4b220584147, replyNumber=0, likeNumber=49, createdTime=2021-02-01, rootId=0, userName=李研东, userId=a68823222118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4b220584147, moduleTitle=ASCO GI 2020：dostarlimab在错配修复缺陷（dMMR）实体瘤取得积极疗效数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4b220584147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645535, encodeId=bbd41645535c0, content=<a href='/topic/show?id=20c296e40e2' target=_blank style='color:#2F92EE;'>#错配修复缺陷#</a>, objectTitle=Acta Neuropathologica: 原发性错配修复缺陷型IDH突变体星形细胞瘤（PMMRDIA）是一种预后不良的独特类型, objectType=article, longId=203736, objectId=8b6e203e36d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b6e203e36d5, replyNumber=0, likeNumber=45, createdTime=2021-08-30, rootId=0, userName=李研东, userId=a68823222118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b6e203e36d5, moduleTitle=Acta Neuropathologica: 原发性错配修复缺陷型IDH突变体星形细胞瘤（PMMRDIA）是一种预后不良的独特类型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b6e203e36d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645533, encodeId=5af716455332c, content=<a href='/topic/show?id=20c296e40e2' target=_blank style='color:#2F92EE;'>#错配修复缺陷#</a>, objectTitle=JCO：Pembrolizumab治疗难治性，微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的II期开放标签研究：KEYNOTE-164, objectType=article, longId=183247, objectId=74bf18324ece, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74bf18324ece, replyNumber=0, likeNumber=53, createdTime=2020-01-17, rootId=0, userName=李研东, userId=a68823222118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74bf18324ece, moduleTitle=JCO：Pembrolizumab治疗难治性，微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的II期开放标签研究：KEYNOTE-164, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74bf18324ece)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645532, encodeId=ab621645532b6, content=<a href='/topic/show?id=20c296e40e2' target=_blank style='color:#2F92EE;'>#错配修复缺陷#</a>, objectTitle=SCIENCE：肿瘤错配修复缺陷影响抗PD-1免疫疗法效果, objectType=article, longId=165371, objectId=e9451653e124, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9451653e124, replyNumber=0, likeNumber=40, createdTime=2020-01-31, rootId=0, userName=李研东, userId=a68823222118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9451653e124, moduleTitle=SCIENCE：肿瘤错配修复缺陷影响抗PD-1免疫疗法效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9451653e124)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645531, encodeId=b32716455317e, content=<a href='/topic/show?id=20c296e40e2' target=_blank style='color:#2F92EE;'>#错配修复缺陷#</a>, objectTitle=JCO：功能修复分析帮助诊断非肿瘤组织的错配修复缺陷, objectType=article, longId=157424, objectId=049415e424e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=049415e424e7, replyNumber=0, likeNumber=33, createdTime=2019-01-29, rootId=0, userName=李研东, userId=a68823222118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=049415e424e7, moduleTitle=JCO：功能修复分析帮助诊断非肿瘤组织的错配修复缺陷, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=049415e424e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

错配修复缺陷

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#新辅助治疗# #帕博利珠单抗# #错配修复缺陷# #微卫星不稳定高#

JCO：新辅助帕博利珠单抗治疗局部错配修复缺陷(dMMR)/微卫星不稳定高(MSI-H)实体瘤

2024-03-11发表于上海

李研东 (审核中...)

前往app查看评论内容

#错配修复缺陷#

Lancet Oncol：派姆单抗 vs 化疗治疗微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的长期预后

2022-06-11

李研东 (审核中...)

前往app查看评论内容

#错配修复缺陷#

Nat Cancer：化疗和错配修复缺陷协同促进TP53突变的发生和急性淋巴细胞白血病的复发

2022-05-23

李研东 (审核中...)

前往app查看评论内容

#错配修复缺陷#

复发或晚期错配修复缺陷的子宫内膜癌：Dostarlimab的临床活性和安全性

2021-08-17

李研东 (审核中...)

前往app查看评论内容

#错配修复缺陷#

Oncologist：Nivolumab加低剂量Ipilimumab为既往治疗的微卫星不稳定及高/错配修复缺陷型转移性结直肠癌患者提供新的治疗选择

2020-12-19

李研东 (审核中...)

前往app查看评论内容

#错配修复缺陷#

ASCO GI 2020：dostarlimab在错配修复缺陷（dMMR）实体瘤取得积极疗效数据

2021-02-01

李研东 (审核中...)

前往app查看评论内容

#错配修复缺陷#

Acta Neuropathologica: 原发性错配修复缺陷型IDH突变体星形细胞瘤（PMMRDIA）是一种预后不良的独特类型

2021-08-30

李研东 (审核中...)

前往app查看评论内容

#错配修复缺陷#

JCO：Pembrolizumab治疗难治性，微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的II期开放标签研究：KEYNOTE-164

2020-01-17

李研东 (审核中...)

前往app查看评论内容

#错配修复缺陷#

SCIENCE：肿瘤错配修复缺陷影响抗PD-1免疫疗法效果

2020-01-31

李研东 (审核中...)

前往app查看评论内容

#错配修复缺陷#

JCO：功能修复分析帮助诊断非肿瘤组织的错配修复缺陷

2019-01-29

科室
- - 订阅+
  - 更多科室
工具
服务